Pharmaceuticalization of Society in Context: Theoretical, Empirical and Health Dimensions
Pharmaceuticalization of Society in Context: Theoretical, Empirical and Health Dimensions
复制标题
DOI：
10.1177/0038038510369368
复制
发表时间：
2010-08-01
影响因子：
2.9
通讯作者：
Abraham, John
中科院分区：
文献类型：
--
作者：
Abraham, John
社会学对药物的兴趣已经加强，提高了对“药物化”的认识。有人认为，制药应参照五个主要的生物社会学解释因素：生物医学，医疗化，制药业的推广和营销，消费主义，和监管国家的意识形态或政策来理解。生物医学主义的论点声称，药物治疗的扩大反映了生物医学科学在满足健康需要方面的进步，这一论点被认为是一个薄弱的解释因素，因为制药业的大量增长与科学证据不一致，而且因为在整个部门，包括主要健康需要领域，提供重大治疗进步的药物创新一直在下降。消费主义的某些因素破坏了药物化，甚至在某些治疗子领域引起去药物化。然而，消费主义的其他方面，以及行业推广，医疗化和放松管制的国家政策被认为是增加药物化的驱动因素，其方式在很大程度上是外部的，或次优的，为了公共卫生的利益，显着的治疗进展。
Sociological interest in pharmaceuticals has intensified, heightening awareness of 'pharmaceuticalization'. It is argued that pharmaceuticalization should be understood by reference to five main biosociological explanatory factors: biomedicalism, medicalization, pharmaceutical industry promotion and marketing, consumerism, and regulatory-state ideology or policy. The biomedicalism thesis, which claims that expansion of drug treatment reflects advances in biomedical science to meet health needs, is found to be a weak explanatory factor because a significant amount of growth in pharmaceuticalization is inconsistent with scientific evidence, and because drug innovations offering significant therapeutic advance have been declining across the sector, including areas of major health need. Some elements of consumerism have undermined pharmaceuticalization, even causing de-pharmaceuticalization in some therapeutic sub-fields. However, other aspects of consumerism, together with industry promotion, medicalization, and deregulatory state policies are found to be drivers of increased pharmaceuticalization in ways that are largely outside, or suboptimal for, significant therapeutic advances in the interests of public health.